Malignant ascites
Information
- Disease name
- Malignant ascites
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06266091 | Active, not recruiting | Phase 2 | Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody | November 24, 2021 | December 31, 2024 |
| NCT04051112 | Completed | Phase 1 | Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites | September 28, 2019 | April 21, 2022 |
| NCT00326885 | Completed | Phase 2 | Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | June 2006 | August 2010 |
| NCT01200121 | Completed | Phase 2 | Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers | February 2010 | December 2014 |
| NCT00822809 | Completed | Phase 3 | CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | December 2008 | April 2011 |
| NCT01327235 | Completed | Phase 2 | Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites | March 2011 | July 2014 |
| NCT01532427 | Completed | ALFApump System Post Marketing Surveillance Registry | June 2012 | July 8, 2019 | |
| NCT00836654 | Completed | Phase 2/Phase 3 | Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group | September 2004 | November 2006 |
| NCT03200106 | Completed | Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites | August 1, 2017 | March 31, 2018 | |
| NCT04032600 | Completed | N/A | Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics | August 1, 2017 | September 9, 2019 |
| NCT05745233 | Enrolling by invitation | N/A | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites | January 1, 2021 | December 2026 |
| NCT05501340 | Not yet recruiting | Phase 1/Phase 2 | PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites | September 1, 2022 | September 1, 2024 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT05477927 | Recruiting | Phase 1 | Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases | November 28, 2023 | December 31, 2024 |
| NCT02724683 | Recruiting | Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter. | January 2016 | December 2023 | |
| NCT06200376 | Recruiting | Phase 1 | A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer | September 28, 2023 | December 2024 |
| NCT06016179 | Recruiting | Phase 1 | Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer | January 30, 2024 | January 2027 |
| NCT04326946 | Recruiting | International Alfapump Cohort Study | August 14, 2018 | December 31, 2025 | |
| NCT06433869 | Recruiting | Phase 2 | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites | December 14, 2023 | December 31, 2026 |
| NCT06432296 | Recruiting | Phase 3 | Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody | March 20, 2024 | November 11, 2025 |
| NCT02122185 | Suspended | Phase 2 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | February 25, 2015 | February 25, 2025 |
| NCT00028782 | Terminated | N/A | EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer | October 2001 | |
| NCT01077063 | Terminated | N/A | An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites | February 2010 | August 2013 |
| NCT01262612 | Terminated | Phase 2 | Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion | April 2010 | |
| NCT02496286 | Terminated | Phase 1 | Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites | June 2015 | August 2015 |
| NCT04501744 | Unknown status | Phase 1 | A Study of M701 (EpCAM and CD3) in Malignant Ascites | October 30, 2018 | June 30, 2021 |
| NCT02530398 | Unknown status | Phase 1 | A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites | July 2015 | June 2018 |
| NCT01854866 | Unknown status | Phase 2 | Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion | May 2013 | March 2014 |
| NCT03736122 | Unknown status | Phase 1/Phase 2 | A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | January 2019 | January 2022 |
| NCT03550560 | Unknown status | EUS-Guided Drainage of Refractory Malignant Ascites | September 1, 2018 | September 1, 2019 | |
| NCT03230708 | Unknown status | Phase 1/Phase 2 | Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites | May 1, 2017 | February 1, 2018 |
| NCT03020979 | Unknown status | Phase 2 | A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites | January 2017 | December 2019 |
| NCT04076566 | Withdrawn | Malignant Ascites Alfapump® Study | May 31, 2020 | March 2022 | |
| NCT00908219 | Withdrawn | Phase 2 | A Study of Bevacizumab to Prevent Malignant Ascites | July 2009 | February 2011 |